Literature DB >> 31339297

Identification of AV-1451 as a Weak, Nonselective Inhibitor of Monoamine Oxidase.

Lindsey R Drake1, Jonathan M Pham2, Timothy J Desmond2, Andrew V Mossine2, So Jeong Lee2, Michael R Kilbourn2, Robert A Koeppe2, Allen F Brooks2, Peter J H Scott1,2.   

Abstract

[18F]AV-1451 is one of the most widely used radiotracers for positron emission tomography (PET) imaging of tau protein aggregates in neurodegenerative disorders. While the radiotracer binds with high affinity to tau neurofibrillary tangles, extensive clinical studies have simultaneously revealed off-target tracer accumulation in areas of low tau burden such as the basal ganglia and choroid plexus. Though there are a number of possible reasons for this accumulation, it is often attributed to off-target binding to monoamine oxidase (MAO). In this paper, we investigate the association between [18F]AV-1451 and MAO through (i) enzyme inhibition assays, (ii) autoradiography with postmortem tissue samples, and (iii) nonhuman primate PET imaging. We confirm that [18F]AV-1451 is a weak inhibitor of MAO-A and -B and that MAO inhibitors can alter binding of [18F]AV-1451 in autoradiography and in vivo PET imaging.

Entities:  

Keywords:  Alzheimer’s disease; flortaucipir; monoamine oxidase (MAO); positron emission tomography (PET) imaging; tau PET

Year:  2019        PMID: 31339297     DOI: 10.1021/acschemneuro.9b00326

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  20 in total

1.  [18F]-AV-1451 tau PET imaging in Alzheimer's disease and suspected non-AD tauopathies using a late acquisition time window.

Authors:  Julien Lagarde; Pauline Olivieri; Fabien Caillé; Philippe Gervais; Jean-Claude Baron; Michel Bottlaender; Marie Sarazin
Journal:  J Neurol       Date:  2019-09-18       Impact factor: 4.849

2.  Structure-Activity Relationships of Radioiodinated 6,5,6-Tricyclic Compounds for the Development of Tau Imaging Probes.

Authors:  Hiroyuki Watanabe; Haruka Tatsumi; Sho Kaide; Yoichi Shimizu; Shimpei Iikuni; Masahiro Ono
Journal:  ACS Med Chem Lett       Date:  2020-01-09       Impact factor: 4.345

Review 3.  Radioactive synthesis of tau PET imaging agent 18F-AV-1451 and its role in monitoring the progression of Alzheimer's disease and supporting differential diagnosis.

Authors:  Wenyan Zhang; Shuoyan Xu; Hongmei Yu; Xuena Li; Zhuangzhuang Jin; Yaming Li; Zhiyi He
Journal:  Ann Nucl Med       Date:  2021-01-18       Impact factor: 2.668

4.  Associations between near end-of-life flortaucipir PET and postmortem CTE-related tau neuropathology in six former American football players.

Authors:  Michael L Alosco; Yi Su; Thor D Stein; Eric M Reiman; Ann C McKee; Robert A Stern; Hillary Protas; Jonathan D Cherry; Charles H Adler; Laura J Balcer; Charles Bernick; Surya Vamsi Pulukuri; Bobak Abdolmohammadi; Michael J Coleman; Joseph N Palmisano; Yorghos Tripodis; Jesse Mez; Gil D Rabinovici; Kenneth L Marek; Thomas G Beach; Keith A Johnson; Bertrand Russell Huber; Inga Koerte; Alexander P Lin; Sylvain Bouix; Jeffrey L Cummings; Martha E Shenton
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-09-24       Impact factor: 10.057

5.  Longitudinal flortaucipir ([18F]AV-1451) PET uptake in semantic dementia.

Authors:  Rene L Utianski; Hugo Botha; Jennifer L Whitwell; Peter R Martin; Christopher G Schwarz; Joseph R Duffy; Heather M Clark; Anthony J Spychalla; Matthew L Senjem; Ronald C Petersen; David S Knopman; Clifford R Jack; Val J Lowe; Keith A Josephs
Journal:  Neurobiol Aging       Date:  2020-04-18       Impact factor: 4.673

6.  18F-flortaucipir PET to autopsy comparisons in Alzheimer's disease and other neurodegenerative diseases.

Authors:  David N Soleimani-Meigooni; Leonardo Iaccarino; Renaud La Joie; Suzanne Baker; Viktoriya Bourakova; Adam L Boxer; Lauren Edwards; Rana Eser; Maria-Luisa Gorno-Tempini; William J Jagust; Mustafa Janabi; Joel H Kramer; Orit H Lesman-Segev; Taylor Mellinger; Bruce L Miller; Julie Pham; Howard J Rosen; Salvatore Spina; William W Seeley; Amelia Strom; Lea T Grinberg; Gil D Rabinovici
Journal:  Brain       Date:  2020-12-05       Impact factor: 13.501

7.  Evaluation of [18F]-N-Methyl lansoprazole as a Tau PET Imaging Agent in First-in-Human Studies.

Authors:  Vasko Kramer; Allen F Brooks; Arlette Haeger; Rodrigo O Kuljis; Waqas Rafique; Robert A Koeppe; David M Raffel; Kirk A Frey; Horacio Amaral; Peter J H Scott; Patrick J Riss
Journal:  ACS Chem Neurosci       Date:  2020-01-15       Impact factor: 4.418

Review 8.  An Update on the State of Tau Radiotracer Development: a Brief Review.

Authors:  Grant Rigney; Cyrus Ayubcha; Thomas J Werner; Abass Alavi
Journal:  Mol Imaging Biol       Date:  2021-05-13       Impact factor: 3.488

9.  Development and evaluation of [125 I]IPPI for Tau imaging in postmortem human Alzheimer's disease brain.

Authors:  Jogeshwar Mukherjee; Christopher Liang; Krystal K Patel; Phuc Q Lam; Rommani Mondal
Journal:  Synapse       Date:  2020-08-06       Impact factor: 2.562

Review 10.  Tau strains shape disease.

Authors:  Jaime Vaquer-Alicea; Marc I Diamond; Lukasz A Joachimiak
Journal:  Acta Neuropathol       Date:  2021-04-08       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.